Tech has dominated this market for years, but it's not the only game left. Small caps outperformed in 2026, the Magnificent Seven has cooled, and money is starting to spread into corners of the market that retail investors rarely explore. Health care, insurance and regional banking are all quietly growing before the crowd.
That's the setup Oxford Club Chief Income Strategist Marc Lichtenfeld is currently watching. His opinion: the fields that work today will not remain secret for long, and are placed early, before the next rotation becomes obvious, that is where the real edge lies.
Why Diversity Still Matters in a Single Sector Market
The focus feels good when you climb. Artificial intelligence stocks have proven that this year, and it's tempting to let one winning trade be the bulk of a portfolio.
The problem appears on the way down. Stocks climb the ladder, but cash goes down—and a sector that's been hot for a while tends to fall hard and fast when it finally turns around. Investors who tend to buy every dip are often caught waiting for a bounce that doesn't happen as quickly as they expect.
That's what trap concentration sets are. It works until it doesn't, and by then it's often too late to turn clean.
Lichtenfeld's point is not to dismiss technology. It's to ensure that the portfolio has other legs to stand on when one leg falters, something that is already working quietly in sectors that many retail investors haven't gone back to until now.
Ligand Pharmaceuticals Turns Drug Risk Into Someone Else's Problem
Health care tends to hold up in any economy, recession or not, because people don't stop needing medicine. Within that sector, Ligand Pharmaceuticals NASDAQ: LGND stands out with a business model that looks more like a royal company than a traditional biotech.
Ligand Pharmaceuticals Today
Ligand Pharmaceuticals
As of 07/10/2026 04:00 PM Eastern
- 52 week interval
- $120.68
▼
$326.63
- The P/E ratio
- 42.91
- Target Value
- $292.86
Instead of spending years and billions to push a single drug through trials, a process that can take eight to 10 years, Ligand acquires the original drug rights and licenses them. The company that approves the drug bears the development risk and costs. Ligand collects royalty.
The market is priced for high growth. Management expects profits to triple by 2030 and quadruple by 2032, supported by more than 100 drugs already on the market or in development and an 80-strong team.
The company has been profitable in nine of the past ten years, with approximately $780 million in cash.
Shares are already underperforming, which is part of why analyst price targets are weighing on the stock. Lichtenfeld says that's normal: Wall Street tends to raise targets after a move, not before. Short interest sitting around 9% of the float adds another wrinkle. If the stock continues to rise, short sellers under pressure may eventually be forced to cover it, adding fuel to the move. What might change the attitude is a licensing deal that discourages or slows down royalty growth. What you need to watch is whether the earnings match those triple or quadruple assumptions.
Aflac Is A Hidden Ratio Play Inside An Insurance Stock
Insurance doesn't generate the same headlines as biotech, but the setup is compelling when interest rates remain high. Insurers invest customer premiums in savings, interest-bearing assets, so higher rates increase the margin between what they collect and what they pay out.
Aflac Today
- 52 week interval
- $96.95
▼
$122.80
- Dividend Yield
- 2.00%
- The P/E ratio
- 13.85
- Target Value
- $114.50
Aflac Incorporated NYSE: AFL equaling that setup and adding record profits—44 straight years of increases—and a strong Japanese business and a growing pet insurance line, the global market is projected to double to $17.5 billion by 2030. A very low debt-to-equity ratio compared to peers gives the company room to grow when opportunities arise.
Wall Street is skeptical here, too. With only four of the 13 analysts rating the stock a Buy, Lichtenfeld puts it more as an upside if sentiment is changing than a warning sign. Profits are expected to grow by 20% between 2026 and 2029, a more stable and less favorable trend than Ligand's.
What could change the story is the continued decline in interest rates, which would put pressure on that investment segment. What you can watch is continued budget growth around Japan's insurance and pet segments.
Atlantic Union Bankshares Offers Slow, Steady Compounding
Atlantic Union Bankshares Today
Atlantic Union Bankshares
- 52 week interval
- $30.39
▼
$43.62
- Dividend Yield
- 3.52%
- The P/E ratio
- 17.80
- Target Value
- $43.63
Regional banks benefit from the same rate as insurance, along with Atlantic Union Bankshares NYSE: AUB it's a name most investors outside of the Mid-Atlantic have never heard of. The Virginia-based bank has operated for 124 years under just five CEOs, a streak that shows in the numbers.
Its cost of deposits is about 20 points below the national average, non-performing loans remain at a low 0.36% of the portfolio, and net charges are close to zero at 0.02%. Executives expect book value, the traditional way of informing banks, to grow by 12% to 15% this year.
has paid dividends of about 3.5%, with annual increases over the past 15 years and a recent increase of nearly 10%.
This is not a stock built for a quick double. It is designed to integrate. What could change sentiment is an increase in loan losses or a sharp decline in prices. What you can see is that tangible book value growth is close to that double-digit target.
Where Real Money Is Made
None of these three will go as AI trading, and that's the point. Ligand offers biotech-style growth without the full biotech risk. Aflac and Atlantic Union offer the kind of grinding, dividend-fueled consolidation that builds real wealth over a decade, not a quarter. Stay diversified, because that's what keeps the portfolio stable when the hot sector ends up cooling.
Before you consider Aflac, you'll want to hear this.
MarketBeat tracks Wall Street's top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aflac wasn't on the list.
Although Aflac currently has a hold rating among analysts, senior analysts believe these five stocks are better buys.
View Five Stocks Here
With the proliferation of data centers and electric vehicles, the power grid will become even more complex. Download this report to learn how energy stocks can play a role in your portfolio as global energy demand continues to grow.
Get This Free Report
